CLINCHOICE, a clinical trial services provider backed by Goldman Sachs Group, is considering a Hong Kong initial public (IPO) offering as soon as next year, according to people familiar with the matter.
CLINCHOICE, a clinical trial services provider backed by Goldman Sachs Group, is considering a Hong Kong initial public (IPO) offering as soon as next year, according to people familiar with the matter.